I-Corps: In-vitro tool that provides multiparametric information in real-time to determine the efficacy and toxicity of a new drug

I-Corps项目的更广泛影响/商业潜力在于改进癌症、心脏病和中风等疾病的更有效药物治疗（例如疗法或再生医学方法）的开发。该设备提供必要的信息，以确定在药物开发的早期阶段，如果新产品将提供足够的增益或益处。预计该技术将简化数据处理，同时提供高质量，成本效益和时间效率的方法。这种方法将节省可用于开发新产品的物质资源和人员。这种新系统的优势将缩短新产品进入市场的时间，同时有助于为癌症和其他疾病提供更有效的治疗方法，而且毒副作用更小。这个I-Corps项目将提供一个新的体外工具，能够收集多个参数的信息，以确定新药的疗效和毒性。这项技术提供了收集细胞对（生物）化学和物理刺激反应的连续和实时数据的手段。与许多依赖于在实验结束时（终点）收集数据的传统检测方法相反，该系统连续收集数据，以减少样本数量提供细胞反应的动态描述。该技术还将利用对电池行为数据的连续访问，为阻抗谱型测量开发数据分析方法。将这一研究工具发展成一个更自动化的系统将扩大其影响和接受度，不仅在生物制药行业，而且在学术和生物医学环境以及生物技术行业。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this I-Corps project is in improving the development of more effective drug treatments (e.g., therapeutics or regenerative medicine approaches) for diseases such as cancer, heart disease, and stroke. This device provides the necessary information to determine, at an early stage in the drug development, if the new product will provide sufficient gain or benefit. It is expected that this technology will simplify data processing while providing a high quality, cost-effective, and time-efficient approach. This approach will free material resources and personnel that can be devoted to the development of new products. The advantages of this new system will reduce the time for new products to reach the marketplace while helping to provide higher efficacy treatments for cancer and other diseases with less toxic side effects.This I-Corps project will provide a new in vitro tool with the capability of gathering information on multiple parameters to determine the efficacy and toxicity of new drugs. This technology provides the means for collecting data on cell responses to (bio)chemical and physical stimuli continuously and in real-time. Contrary to many conventional detection methods that rely on collecting data at the end of the experiment (endpoint), this system collects data continuously, providing a dynamic account of cell responses with a reduced number of samples. This technology will also leverage continuous access to cell behavior data to enable the development of a data analytics approach for impedance spectroscopy-type measurements. The development of this research tool into a more automated system will broaden its impact and acceptance not only in the biopharmaceutical industry but also in academic and biomedical environments and the biotechnology industry.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.